Abstract A209: Predicting genetic drivers of MEK dependency with gene expression.
Jonathan R. Dry , Darren Hodgson , Roz Brant , Tom Liptrot
Molecular Cancer Therapeutics 12
2013
Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer: A Preplanned Retrospective Analysis of Outcomes by BRCA Status in a Randomised Phase 2 Trial
Jonathan Ledermann , Philipp Harter , Charlie Gourley , Michael Friedlander
Lancet Oncology 15 ( 8) 852 -861
1,562
2014
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
Sophie E Willis , Claudia Winkler , Martine P Roudier , Tarrion Baird
British Journal of Cancer 125 ( 12) 1666 -1676
6
2021
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Christopher Abbosh , Alexander M Frankell , Thomas Harrison , Judit Kisistok
Nature 616 ( 7957) 553 -562
94
2023
Abstract PR003: T cell receptor repertoire and diversity are prognostic markers in bladder cancer
Nanna Kristjánsdóttir , Asbjørn Kjær , Iver Nordentoft , Randi I Juul
Clinical Cancer Research 30 ( 10_Supplement) PR003 -PR003
2024
Peripheral T cell receptor repertoire diversity is associated with outcome in bladder cancer
Asbjørn Kjær , Nanna Kristjánsdóttir , Iver Nordentoft , Randi Istrup Juul
Cancer Research 84 ( 6_Supplement) 5216 -5216
2024
Abstract CT238: Associations of ctDNA levels during neoadjuvant treatment with pathological response in patients with resectable NSCLC from the phase 3 AEGEAN trial
Davina Gale , Zhou Zhu , Zhongwu Lai , Martin Reck
Cancer Research 84 ( 7_Supplement) CT238 -CT238
2024
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
Chris Abbosh , Darren Hodgson , Gary J Doherty , Davina Gale
Trends in Cancer
2024
Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinic
Darren Hodgson , Helen Mason , Lenka Oplustilova , Chris Harbron
Cancer Research 74 ( 19_Supplement) 2398 -2398
9
2014
Misclassification of clonal hematopoietic mutations as tumor-derived confound accurate ctDNA-response assessment in patients with metastatic non-small-cell lung cancer: analyses from the phase 3 MYSTIC trial
Chris Abbosh , Michael Kuziora , Daniel Stetson , Zhongwu Lai
Cancer Research 83 ( 7_Supplement) 2299 -2299
1
2023
Background variability in plasma ctDNA levels in patients with advanced lung cancer in the absence of treatment
Diana M Vega , Aleksandra Markovets , Christopher Abbosh , Katie Quinn
Cancer Research 83 ( 7_Supplement) 1052 -1052
2023
Exploring ATM deficiency as a potential therapeutic target for the PARP inhibitor olaparib in head and neck squamous cell carcinoma
Joana M Senra , Emma L Donald , Victoria S Williams , Helen Wombwell
Cancer Research 71 ( 8_Supplement) 5088 -5088
1
2011
Tumor-naïve pre-surgical ctDNA detection is prognostic in clinical stage I lung adenocarcinoma
Tae Hee Hong , Soohyun Hwang , Abhijit Dasgupta , Christopher Abbosh
2024
Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients
Helen Angell , Vidalba Rocher Ros , Nathan Standifer , ZW Lai
JOURNAL FOR IMMUNOTHERAPY OF CANCER 5
2017
Autophagy Signal
Noel Clarke , Pawel Wiechno , Boris Alekseev , Nuria Sala
Identifying pre-clinical predictive biomarkers for the PARP inhibitor olaparib
Jonathan R Dry , Alan Lau , Charlotte Knights , Chris Harbron
Cancer Research 70 ( 8_Supplement) 3497 -3497
1
2010
Aberrant expression of CXCL13 in chronic wounds and keloid scars
Neil French , Darren Hodgson , Haris Rathur , Rayaz Malik
WOUND REPAIR AND REGENERATION 16 ( 2) A17 -A17
2008
Abstract LB293: The evolution of MRD assays: Moving beyond the tumor-Informed bespoke NGS panel
Paul Labrousse , Daniel Stetson , James Hadfield , Chris Abbosh
Cancer Research 83 ( 8_Supplement) LB293 -LB293
2023
Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets
Zhongwu Lai , Matthew Brosnan , Ethan S Sokol , Mingchao Xie
BMC cancer 22 1 -13
14
2022
Homologous recombination repair gene mutation characterization by liquid biopsy: a phase II trial of olaparib and abiraterone in metastatic castrate-resistant prostate cancer
T Hedley Carr , Carrie Adelman , Alan Barnicle , Iwanka Kozarewa
Cancers 13 ( 22) 5830 -5830
22
2021